AMNEAL FDA Friday, March 5, 2021 +0.30 Positive

FDA Approves Unknown Drug — AMNEAL

Amneal Pharmaceuticals has received FDA approval for generic drug ANDA211374, a development that positions the company to capture market share amidst ongoing supply chain constraints. This regulatory clearance is poised to provide additional revenue streams for the manufacturer as generic demand remains robust.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed